APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Opioid Receptor Agonist

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Opioid Receptor Agonist Market Analysis and Forecast 2026-2032

Report ID 174019360230 December 2025196 pages

Choose your research edition.

Industry ResearchOpioid Receptor Agonist Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Receptor Agonist Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Opioid Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Receptor Agonist Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Receptor Agonist Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Opioid Receptor Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Opioid Receptor Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Opioid Receptor Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Opioid Receptor Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Opioid Receptor Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Opioid Receptor Agonist include Allergan, DAIICHI SANKYO COMPANY, Endo Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, Indivior, Mylan N.V., Piramal Critical Care and Purdue Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Opioid Receptor Agonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Opioid Receptor Agonist, also provides the sales of main regions and countries. Of the upcoming market potential for Opioid Receptor Agonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Opioid Receptor Agonist sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Opioid Receptor Agonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Opioid Receptor Agonist sales, projected growth trends, production technology, application and end-user industry.

Opioid Receptor Agonist Segment by Company

Allergan

DAIICHI SANKYO COMPANY

Endo Pharmaceuticals

Fresenius Kabi

Hikma Pharmaceuticals

Indivior

Mylan N.V.

Piramal Critical Care

Purdue Pharma

Sun Pharmaceutical Industries

Tris Pharma

US WorldMeds

Pfizer

Johnson & Johnson

Teva Pharmaceutical Industries

Opioid Receptor Agonist Segment by Type

Morphine

Codeine

Fentanyl

Others

Opioid Receptor Agonist Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Opioid Receptor Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Receptor Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Opioid Receptor Agonist in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Opioid Receptor Agonist manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Opioid Receptor Agonist sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Opioid Receptor Agonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Morphine Major Manufacturers Table 3. Codeine Major Manufacturers Table 4. Fentanyl Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Opioid Receptor Agonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Retail Pharmacy Major Manufacturers Table 8. Online Pharmacy Major Manufacturers Table 9. Hospital Pharmacy Major Manufacturers Table 10. Opioid Receptor Agonist Industry Trends Table 11. Opioid Receptor Agonist Industry Drivers Table 12. Opioid Receptor Agonist Industry Opportunities and Challenges Table 13. Opioid Receptor Agonist Industry Restraints Table 14. Global Opioid Receptor Agonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Opioid Receptor Agonist Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Opioid Receptor Agonist Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Opioid Receptor Agonist Revenue Market Share by Region (2021-2026) Table 18. Global Opioid Receptor Agonist Revenue Market Share by Region (2027-2032) Table 19. Global Opioid Receptor Agonist Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Opioid Receptor Agonist Sales by Region (2021-2026) & (K Units) Table 21. Global Opioid Receptor Agonist Sales by Region (2027-2032) & (K Units) Table 22. Global Opioid Receptor Agonist Sales Market Share by Region (2021-2026) Table 23. Global Opioid Receptor Agonist Sales Market Share by Region (2027-2032) Table 24. Global Opioid Receptor Agonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Opioid Receptor Agonist Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Opioid Receptor Agonist Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Opioid Receptor Agonist Sales Market Share by Manufacturers (2021-2026) Table 28. Global Opioid Receptor Agonist Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Opioid Receptor Agonist Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Opioid Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Opioid Receptor Agonist Manufacturers, Product Type & Application Table 32. Global Opioid Receptor Agonist Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Opioid Receptor Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Opioid Receptor Agonist Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2026) Table 39. Global Opioid Receptor Agonist Revenue Market Share by Type (2027-2032) Table 40. Global Opioid Receptor Agonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 42. Global Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 43. Global Opioid Receptor Agonist Sales Market Share by Type (2021-2026) Table 44. Global Opioid Receptor Agonist Sales Market Share by Type (2027-2032) Table 45. Global Opioid Receptor Agonist Price by Type (2021-2026) & (US$/Unit) Table 46. Global Opioid Receptor Agonist Price by Type (2027-2032) & (US$/Unit) Table 47. Global Opioid Receptor Agonist Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2026) Table 51. Global Opioid Receptor Agonist Revenue Market Share by Application (2027-2032) Table 52. Global Opioid Receptor Agonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 54. Global Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 55. Global Opioid Receptor Agonist Sales Market Share by Application (2021-2026) Table 56. Global Opioid Receptor Agonist Sales Market Share by Application (2027-2032) Table 57. Global Opioid Receptor Agonist Price by Application (2021-2026) & (US$/Unit) Table 58. Global Opioid Receptor Agonist Price by Application (2027-2032) & (US$/Unit) Table 59. Allergan Company Information Table 60. Allergan Business Overview Table 61. Allergan Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Allergan Opioid Receptor Agonist Product Portfolio Table 63. Allergan Recent Development Table 64. DAIICHI SANKYO COMPANY Company Information Table 65. DAIICHI SANKYO COMPANY Business Overview Table 66. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio Table 68. DAIICHI SANKYO COMPANY Recent Development Table 69. Endo Pharmaceuticals Company Information Table 70. Endo Pharmaceuticals Business Overview Table 71. Endo Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 73. Endo Pharmaceuticals Recent Development Table 74. Fresenius Kabi Company Information Table 75. Fresenius Kabi Business Overview Table 76. Fresenius Kabi Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Fresenius Kabi Opioid Receptor Agonist Product Portfolio Table 78. Fresenius Kabi Recent Development Table 79. Hikma Pharmaceuticals Company Information Table 80. Hikma Pharmaceuticals Business Overview Table 81. Hikma Pharmaceuticals Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio Table 83. Hikma Pharmaceuticals Recent Development Table 84. Indivior Company Information Table 85. Indivior Business Overview Table 86. Indivior Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Indivior Opioid Receptor Agonist Product Portfolio Table 88. Indivior Recent Development Table 89. Mylan N.V. Company Information Table 90. Mylan N.V. Business Overview Table 91. Mylan N.V. Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Mylan N.V. Opioid Receptor Agonist Product Portfolio Table 93. Mylan N.V. Recent Development Table 94. Piramal Critical Care Company Information Table 95. Piramal Critical Care Business Overview Table 96. Piramal Critical Care Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Piramal Critical Care Opioid Receptor Agonist Product Portfolio Table 98. Piramal Critical Care Recent Development Table 99. Purdue Pharma Company Information Table 100. Purdue Pharma Business Overview Table 101. Purdue Pharma Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Purdue Pharma Opioid Receptor Agonist Product Portfolio Table 103. Purdue Pharma Recent Development Table 104. Sun Pharmaceutical Industries Company Information Table 105. Sun Pharmaceutical Industries Business Overview Table 106. Sun Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 108. Sun Pharmaceutical Industries Recent Development Table 109. Tris Pharma Company Information Table 110. Tris Pharma Business Overview Table 111. Tris Pharma Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Tris Pharma Opioid Receptor Agonist Product Portfolio Table 113. Tris Pharma Recent Development Table 114. US WorldMeds Company Information Table 115. US WorldMeds Business Overview Table 116. US WorldMeds Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. US WorldMeds Opioid Receptor Agonist Product Portfolio Table 118. US WorldMeds Recent Development Table 119. Pfizer Company Information Table 120. Pfizer Business Overview Table 121. Pfizer Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Pfizer Opioid Receptor Agonist Product Portfolio Table 123. Pfizer Recent Development Table 124. Johnson & Johnson Company Information Table 125. Johnson & Johnson Business Overview Table 126. Johnson & Johnson Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Johnson & Johnson Opioid Receptor Agonist Product Portfolio Table 128. Johnson & Johnson Recent Development Table 129. Teva Pharmaceutical Industries Company Information Table 130. Teva Pharmaceutical Industries Business Overview Table 131. Teva Pharmaceutical Industries Opioid Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio Table 133. Teva Pharmaceutical Industries Recent Development Table 134. North America Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 135. North America Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 136. North America Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 137. North America Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 138. North America Opioid Receptor Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 139. North America Opioid Receptor Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 140. North America Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 141. North America Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 142. North America Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 143. North America Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 144. North America Opioid Receptor Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 145. North America Opioid Receptor Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 146. North America Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America Opioid Receptor Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. North America Opioid Receptor Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. North America Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 150. North America Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 151. North America Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 152. North America Opioid Receptor Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 153. North America Opioid Receptor Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 154. United States Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 155. Canada Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 156. Europe Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 157. Europe Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 158. Europe Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 159. Europe Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 160. Europe Opioid Receptor Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 161. Europe Opioid Receptor Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 162. Europe Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 163. Europe Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 164. Europe Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 165. Europe Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 166. Europe Opioid Receptor Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 167. Europe Opioid Receptor Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 168. Europe Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. Europe Opioid Receptor Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. Europe Opioid Receptor Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. Europe Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 172. Europe Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 173. Europe Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 174. Europe Opioid Receptor Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 175. Europe Opioid Receptor Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 176. Germany Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 177. France Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 178. U.K. Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 179. Italy Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 180. Netherlands Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 181. China Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 182. China Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 183. China Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 184. China Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 185. China Opioid Receptor Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 186. China Opioid Receptor Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 187. China Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 188. China Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 189. China Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 190. China Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 191. China Opioid Receptor Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 192. China Opioid Receptor Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 193. Asia Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 194. Asia Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 195. Asia Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 196. Asia Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 197. Asia Opioid Receptor Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 198. Asia Opioid Receptor Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 199. Asia Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 200. Asia Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 201. Asia Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 202. Asia Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 203. Asia Opioid Receptor Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 204. Asia Opioid Receptor Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 205. Asia Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. Asia Opioid Receptor Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. Asia Opioid Receptor Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. Asia Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 209. Asia Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 210. Asia Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 211. Asia Opioid Receptor Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 212. Asia Opioid Receptor Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 213. Japan Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 214. South Korea Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 215. India Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 216. Australia Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 217. China Taiwan Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 218. Southeast Asia Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 219. SAMEA Opioid Receptor Agonist Revenue by Type (2021-2026) & (US$ Million) Table 220. SAMEA Opioid Receptor Agonist Revenue by Type (2027-2032) & (US$ Million) Table 221. SAMEA Opioid Receptor Agonist Sales by Type (2021-2026) & (K Units) Table 222. SAMEA Opioid Receptor Agonist Sales by Type (2027-2032) & (K Units) Table 223. SAMEA Opioid Receptor Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 224. SAMEA Opioid Receptor Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 225. SAMEA Opioid Receptor Agonist Revenue by Application (2021-2026) & (US$ Million) Table 226. SAMEA Opioid Receptor Agonist Revenue by Application (2027-2032) & (US$ Million) Table 227. SAMEA Opioid Receptor Agonist Sales by Application (2021-2026) & (K Units) Table 228. SAMEA Opioid Receptor Agonist Sales by Application (2027-2032) & (K Units) Table 229. SAMEA Opioid Receptor Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 230. SAMEA Opioid Receptor Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 231. SAMEA Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 232. SAMEA Opioid Receptor Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 233. SAMEA Opioid Receptor Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 234. SAMEA Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 235. SAMEA Opioid Receptor Agonist Sales by Country (2021-2026) & (K Units) Table 236. SAMEA Opioid Receptor Agonist Sales by Country (2027-2032) & (K Units) Table 237. SAMEA Opioid Receptor Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 238. SAMEA Opioid Receptor Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 239. Brazil Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 240. Argentina Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 241. Chile Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 242. Colombia Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 243. Peru Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 244. Saudi Arabia Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 245. Israel Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 246. UAE Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 247. Turkey Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 248. Iran Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 249. Egypt Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Table 250. Key Raw Materials Table 251. Raw Materials Key Suppliers Table 252. Opioid Receptor Agonist Distributors List Table 253. Opioid Receptor Agonist Customers List Table 254. Research Programs/Design for This Report Table 255. Authors List of This Report Table 256. Secondary Sources Table 257. Primary Sources List of Figures Figure 1. Opioid Receptor Agonist Image Figure 2. Global Opioid Receptor Agonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Receptor Agonist Market Size Share 2021 VS 2025 VS 2032 Figure 4. Morphine Image Figure 5. Codeine Image Figure 6. Fentanyl Image Figure 7. Others Image Figure 8. Global Opioid Receptor Agonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Opioid Receptor Agonist Market Size Share 2021 VS 2025 VS 2032 Figure 10. Retail Pharmacy Image Figure 11. Online Pharmacy Image Figure 12. Hospital Pharmacy Image Figure 13. Global Opioid Receptor Agonist Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Opioid Receptor Agonist Revenue (2021-2032) & (US$ Million) Figure 15. Global Opioid Receptor Agonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Opioid Receptor Agonist Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Opioid Receptor Agonist Revenue Market Share by Region (2021-2032) Figure 18. Global Opioid Receptor Agonist Sales (2021-2032) & (K Units) Figure 19. Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Opioid Receptor Agonist Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Opioid Receptor Agonist Sales YoY (2021-2032) & (K Units) Figure 22. Europe Opioid Receptor Agonist Sales YoY (2021-2032) & (K Units) Figure 23. China Opioid Receptor Agonist Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Opioid Receptor Agonist Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Opioid Receptor Agonist Sales YoY (2021-2032) & (K Units) Figure 26. Global Opioid Receptor Agonist Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Opioid Receptor Agonist Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Opioid Receptor Agonist Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Opioid Receptor Agonist Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2032) Figure 32. Global Opioid Receptor Agonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Opioid Receptor Agonist Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Opioid Receptor Agonist Sales Market Share by Type (2021-2032) Figure 35. Global Opioid Receptor Agonist Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Opioid Receptor Agonist Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2032) Figure 38. Global Opioid Receptor Agonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Opioid Receptor Agonist Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Opioid Receptor Agonist Sales Market Share by Application (2021-2032) Figure 41. North America Opioid Receptor Agonist Revenue Share by Type (2021-2032) Figure 42. North America Opioid Receptor Agonist Sales Share by Type (2021-2032) Figure 43. North America Opioid Receptor Agonist Revenue Share by Application (2021-2032) Figure 44. North America Opioid Receptor Agonist Sales Share by Application (2021-2032) Figure 45. North America Opioid Receptor Agonist Revenue Share by Country (2021-2032) Figure 46. North America Opioid Receptor Agonist Sales Share by Country (2021-2032) Figure 47. Europe Opioid Receptor Agonist Revenue Share by Type (2021-2032) Figure 48. Europe Opioid Receptor Agonist Sales Share by Type (2021-2032) Figure 49. Europe Opioid Receptor Agonist Revenue Share by Application (2021-2032) Figure 50. Europe Opioid Receptor Agonist Sales Share by Application (2021-2032) Figure 51. Europe Opioid Receptor Agonist Revenue Share by Country (2021-2032) Figure 52. Europe Opioid Receptor Agonist Sales Share by Country (2021-2032) Figure 53. China Opioid Receptor Agonist Revenue Share by Type (2021-2032) Figure 54. China Opioid Receptor Agonist Sales Share by Type (2021-2032) Figure 55. China Opioid Receptor Agonist Revenue Share by Application (2021-2032) Figure 56. China Opioid Receptor Agonist Sales Share by Application (2021-2032) Figure 57. Asia Opioid Receptor Agonist Revenue Share by Type (2021-2032) Figure 58. Asia Opioid Receptor Agonist Sales Share by Type (2021-2032) Figure 59. Asia Opioid Receptor Agonist Revenue Share by Application (2021-2032) Figure 60. Asia Opioid Receptor Agonist Sales Share by Application (2021-2032) Figure 61. Asia Opioid Receptor Agonist Revenue Share by Country (2021-2032) Figure 62. Asia Opioid Receptor Agonist Sales Share by Country (2021-2032) Figure 63. SAMEA Opioid Receptor Agonist Revenue Share by Type (2021-2032) Figure 64. SAMEA Opioid Receptor Agonist Sales Share by Type (2021-2032) Figure 65. SAMEA Opioid Receptor Agonist Revenue Share by Application (2021-2032) Figure 66. SAMEA Opioid Receptor Agonist Sales Share by Application (2021-2032) Figure 67. SAMEA Opioid Receptor Agonist Revenue Share by Country (2021-2032) Figure 68. SAMEA Opioid Receptor Agonist Sales Share by Country (2021-2032) Figure 69. Opioid Receptor Agonist Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Opioid Receptor Agonist Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Morphine
  • Codeine
  • Fentanyl
  • Others
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Allergan
  • DAIICHI SANKYO COMPANY
  • Endo Pharmaceuticals
  • Fresenius Kabi
  • Hikma Pharmaceuticals
  • Indivior
  • Mylan N.V.
  • Piramal Critical Care
  • Purdue Pharma
  • Sun Pharmaceutical Industries
  • Tris Pharma
  • US WorldMeds
  • Pfizer
  • Johnson & Johnson
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Opioid Receptor Agonist Market by Type
  3. 1.2.1 Global Opioid Receptor Agonist Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Morphine
  5. 1.2.3 Codeine
  6. 1.2.4 Fentanyl
  7. 1.2.5 Others
  8. 1.3 Opioid Receptor Agonist Market by Application
  9. 1.3.1 Global Opioid Receptor Agonist Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Retail Pharmacy
  11. 1.3.3 Online Pharmacy
  12. 1.3.4 Hospital Pharmacy
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Opioid Receptor Agonist Market Dynamics
  1. 2.1 Opioid Receptor Agonist Industry Trends
  2. 2.2 Opioid Receptor Agonist Industry Drivers
  3. 2.3 Opioid Receptor Agonist Industry Opportunities and Challenges
  4. 2.4 Opioid Receptor Agonist Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Opioid Receptor Agonist Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Opioid Receptor Agonist Revenue by Region
  3. 3.2.1 Global Opioid Receptor Agonist Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Opioid Receptor Agonist Revenue by Region (2021-2026)
  5. 3.2.3 Global Opioid Receptor Agonist Revenue by Region (2027-2032)
  6. 3.2.4 Global Opioid Receptor Agonist Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Opioid Receptor Agonist Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Opioid Receptor Agonist Sales by Region
  9. 3.4.1 Global Opioid Receptor Agonist Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Opioid Receptor Agonist Sales by Region (2021-2026)
  11. 3.4.3 Global Opioid Receptor Agonist Sales by Region (2027-2032)
  12. 3.4.4 Global Opioid Receptor Agonist Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Opioid Receptor Agonist Revenue by Manufacturers
  2. 4.1.1 Global Opioid Receptor Agonist Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Opioid Receptor Agonist Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Opioid Receptor Agonist Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Opioid Receptor Agonist Sales by Manufacturers
  6. 4.2.1 Global Opioid Receptor Agonist Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Opioid Receptor Agonist Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Opioid Receptor Agonist Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Opioid Receptor Agonist Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Opioid Receptor Agonist Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Opioid Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Opioid Receptor Agonist Manufacturers, Product Type & Application
  13. 4.7 Global Opioid Receptor Agonist Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Opioid Receptor Agonist Market CR5 and HHI
  16. 4.8.2 2025 Opioid Receptor Agonist Tier 1, Tier 2, and Tier 3
5 Opioid Receptor Agonist Market by Type
  1. 5.1 Global Opioid Receptor Agonist Revenue by Type
  2. 5.1.1 Global Opioid Receptor Agonist Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Opioid Receptor Agonist Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Opioid Receptor Agonist Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Opioid Receptor Agonist Sales by Type
  6. 5.2.1 Global Opioid Receptor Agonist Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Receptor Agonist Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Opioid Receptor Agonist Sales Market Share by Type (2021-2032)
  9. 5.3 Global Opioid Receptor Agonist Price by Type
6 Opioid Receptor Agonist Market by Application
  1. 6.1 Global Opioid Receptor Agonist Revenue by Application
  2. 6.1.1 Global Opioid Receptor Agonist Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Opioid Receptor Agonist Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Opioid Receptor Agonist Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Opioid Receptor Agonist Sales by Application
  6. 6.2.1 Global Opioid Receptor Agonist Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Opioid Receptor Agonist Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Opioid Receptor Agonist Sales Market Share by Application (2021-2032)
  9. 6.3 Global Opioid Receptor Agonist Price by Application
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Opioid Receptor Agonist Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 DAIICHI SANKYO COMPANY
  8. 7.2.1 DAIICHI SANKYO COMPANY Company Information
  9. 7.2.2 DAIICHI SANKYO COMPANY Business Overview
  10. 7.2.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio
  12. 7.2.5 DAIICHI SANKYO COMPANY Recent Developments
  13. 7.3 Endo Pharmaceuticals
  14. 7.3.1 Endo Pharmaceuticals Company Information
  15. 7.3.2 Endo Pharmaceuticals Business Overview
  16. 7.3.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  18. 7.3.5 Endo Pharmaceuticals Recent Developments
  19. 7.4 Fresenius Kabi
  20. 7.4.1 Fresenius Kabi Company Information
  21. 7.4.2 Fresenius Kabi Business Overview
  22. 7.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Fresenius Kabi Opioid Receptor Agonist Product Portfolio
  24. 7.4.5 Fresenius Kabi Recent Developments
  25. 7.5 Hikma Pharmaceuticals
  26. 7.5.1 Hikma Pharmaceuticals Company Information
  27. 7.5.2 Hikma Pharmaceuticals Business Overview
  28. 7.5.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio
  30. 7.5.5 Hikma Pharmaceuticals Recent Developments
  31. 7.6 Indivior
  32. 7.6.1 Indivior Company Information
  33. 7.6.2 Indivior Business Overview
  34. 7.6.3 Indivior Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Indivior Opioid Receptor Agonist Product Portfolio
  36. 7.6.5 Indivior Recent Developments
  37. 7.7 Mylan N.V.
  38. 7.7.1 Mylan N.V. Company Information
  39. 7.7.2 Mylan N.V. Business Overview
  40. 7.7.3 Mylan N.V. Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Mylan N.V. Opioid Receptor Agonist Product Portfolio
  42. 7.7.5 Mylan N.V. Recent Developments
  43. 7.8 Piramal Critical Care
  44. 7.8.1 Piramal Critical Care Company Information
  45. 7.8.2 Piramal Critical Care Business Overview
  46. 7.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Piramal Critical Care Opioid Receptor Agonist Product Portfolio
  48. 7.8.5 Piramal Critical Care Recent Developments
  49. 7.9 Purdue Pharma
  50. 7.9.1 Purdue Pharma Company Information
  51. 7.9.2 Purdue Pharma Business Overview
  52. 7.9.3 Purdue Pharma Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Purdue Pharma Opioid Receptor Agonist Product Portfolio
  54. 7.9.5 Purdue Pharma Recent Developments
  55. 7.10 Sun Pharmaceutical Industries
  56. 7.10.1 Sun Pharmaceutical Industries Company Information
  57. 7.10.2 Sun Pharmaceutical Industries Business Overview
  58. 7.10.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  60. 7.10.5 Sun Pharmaceutical Industries Recent Developments
  61. 7.11 Tris Pharma
  62. 7.11.1 Tris Pharma Company Information
  63. 7.11.2 Tris Pharma Business Overview
  64. 7.11.3 Tris Pharma Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Tris Pharma Opioid Receptor Agonist Product Portfolio
  66. 7.11.5 Tris Pharma Recent Developments
  67. 7.12 US WorldMeds
  68. 7.12.1 US WorldMeds Company Information
  69. 7.12.2 US WorldMeds Business Overview
  70. 7.12.3 US WorldMeds Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 US WorldMeds Opioid Receptor Agonist Product Portfolio
  72. 7.12.5 US WorldMeds Recent Developments
  73. 7.13 Pfizer
  74. 7.13.1 Pfizer Company Information
  75. 7.13.2 Pfizer Business Overview
  76. 7.13.3 Pfizer Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Opioid Receptor Agonist Product Portfolio
  78. 7.13.5 Pfizer Recent Developments
  79. 7.14 Johnson & Johnson
  80. 7.14.1 Johnson & Johnson Company Information
  81. 7.14.2 Johnson & Johnson Business Overview
  82. 7.14.3 Johnson & Johnson Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Johnson & Johnson Opioid Receptor Agonist Product Portfolio
  84. 7.14.5 Johnson & Johnson Recent Developments
  85. 7.15 Teva Pharmaceutical Industries
  86. 7.15.1 Teva Pharmaceutical Industries Company Information
  87. 7.15.2 Teva Pharmaceutical Industries Business Overview
  88. 7.15.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
  90. 7.15.5 Teva Pharmaceutical Industries Recent Developments
8 North America
  1. 8.1 North America Opioid Receptor Agonist Market Size by Type
  2. 8.1.1 North America Opioid Receptor Agonist Revenue by Type (2021-2032)
  3. 8.1.2 North America Opioid Receptor Agonist Sales by Type (2021-2032)
  4. 8.1.3 North America Opioid Receptor Agonist Price by Type (2021-2032)
  5. 8.2 North America Opioid Receptor Agonist Market Size by Application
  6. 8.2.1 North America Opioid Receptor Agonist Revenue by Application (2021-2032)
  7. 8.2.2 North America Opioid Receptor Agonist Sales by Application (2021-2032)
  8. 8.2.3 North America Opioid Receptor Agonist Price by Application (2021-2032)
  9. 8.3 North America Opioid Receptor Agonist Market Size by Country
  10. 8.3.1 North America Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Opioid Receptor Agonist Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Opioid Receptor Agonist Market Size by Type
  2. 9.1.1 Europe Opioid Receptor Agonist Revenue by Type (2021-2032)
  3. 9.1.2 Europe Opioid Receptor Agonist Sales by Type (2021-2032)
  4. 9.1.3 Europe Opioid Receptor Agonist Price by Type (2021-2032)
  5. 9.2 Europe Opioid Receptor Agonist Market Size by Application
  6. 9.2.1 Europe Opioid Receptor Agonist Revenue by Application (2021-2032)
  7. 9.2.2 Europe Opioid Receptor Agonist Sales by Application (2021-2032)
  8. 9.2.3 Europe Opioid Receptor Agonist Price by Application (2021-2032)
  9. 9.3 Europe Opioid Receptor Agonist Market Size by Country
  10. 9.3.1 Europe Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Opioid Receptor Agonist Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Opioid Receptor Agonist Market Size by Type
  2. 10.1.1 China Opioid Receptor Agonist Revenue by Type (2021-2032)
  3. 10.1.2 China Opioid Receptor Agonist Sales by Type (2021-2032)
  4. 10.1.3 China Opioid Receptor Agonist Price by Type (2021-2032)
  5. 10.2 China Opioid Receptor Agonist Market Size by Application
  6. 10.2.1 China Opioid Receptor Agonist Revenue by Application (2021-2032)
  7. 10.2.2 China Opioid Receptor Agonist Sales by Application (2021-2032)
  8. 10.2.3 China Opioid Receptor Agonist Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Opioid Receptor Agonist Market Size by Type
  2. 11.1.1 Asia Opioid Receptor Agonist Revenue by Type (2021-2032)
  3. 11.1.2 Asia Opioid Receptor Agonist Sales by Type (2021-2032)
  4. 11.1.3 Asia Opioid Receptor Agonist Price by Type (2021-2032)
  5. 11.2 Asia Opioid Receptor Agonist Market Size by Application
  6. 11.2.1 Asia Opioid Receptor Agonist Revenue by Application (2021-2032)
  7. 11.2.2 Asia Opioid Receptor Agonist Sales by Application (2021-2032)
  8. 11.2.3 Asia Opioid Receptor Agonist Price by Application (2021-2032)
  9. 11.3 Asia Opioid Receptor Agonist Market Size by Country
  10. 11.3.1 Asia Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Opioid Receptor Agonist Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Opioid Receptor Agonist Market Size by Type
  2. 12.1.1 SAMEA Opioid Receptor Agonist Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Opioid Receptor Agonist Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Opioid Receptor Agonist Price by Type (2021-2032)
  5. 12.2 SAMEA Opioid Receptor Agonist Market Size by Application
  6. 12.2.1 SAMEA Opioid Receptor Agonist Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Opioid Receptor Agonist Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Opioid Receptor Agonist Price by Application (2021-2032)
  9. 12.3 SAMEA Opioid Receptor Agonist Market Size by Country
  10. 12.3.1 SAMEA Opioid Receptor Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Opioid Receptor Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Opioid Receptor Agonist Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Opioid Receptor Agonist Value Chain Analysis
  2. 13.1.1 Opioid Receptor Agonist Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Opioid Receptor Agonist Production Mode & Process
  6. 13.2 Opioid Receptor Agonist Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Opioid Receptor Agonist Distributors
  9. 13.2.3 Opioid Receptor Agonist Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst